POPULATION CHARACTERISTICS, HEALTHCARE RESOURCE USE AND COSTS OF HIDRADENTIS SUPPURATIVA IN FRANCE - THE HESTIA STUDY
Author(s)
Gerard De Pouvourville, PhD1, Ziad Reguiai, MD2, Philippe Guillem, MD3, Esther Fabre, PharmD4, Hedia Kridanemiledi, PhD4, Alicia Fravalo, MSc5, Stephane Bouee, MD, MSc5, Laurent Abramowitz, MD6.
1ESSEC Business School, Cergy-Pontoise, France, 2Polyclinique Courlancy-Bezannes, Reims, France, 3Department of Gastroenterology and Proctology, Clinique du Val d'Ouest Ecully, Ecully, France, 4UCB Pharma SA, Colombes, France, 5RWE, CEMKA, Bourg-la-Reine, France, 6Department of Gastroenterology and Proctology, APHP, hôpitaux de Paris, Paris, France.
1ESSEC Business School, Cergy-Pontoise, France, 2Polyclinique Courlancy-Bezannes, Reims, France, 3Department of Gastroenterology and Proctology, Clinique du Val d'Ouest Ecully, Ecully, France, 4UCB Pharma SA, Colombes, France, 5RWE, CEMKA, Bourg-la-Reine, France, 6Department of Gastroenterology and Proctology, APHP, hôpitaux de Paris, Paris, France.
OBJECTIVES: Hidradenitis suppurativa (HS) is a chronic skin disease characterized by painful inflammatory nodules, abscesses and tunnels. The aim of this study was to describe patients living with HS (PLHS), estimate HS-related health care resource use (HCRU) and associated costs in France.
METHODS: Data were extracted from the French national claims database (SNDS) for the period 1/1/2008-31/12/2023. PLHS were patients aged ≥13 years identified using an algorithm based on the L73.2 ICD‑10 code, HS‑specific treatments and procedures, alive on 1/1/2023. Controls are subject without HS and matched to the PLHS according to year of birth and gender. The cost is reported from a societal perspective.
RESULTS: 64,189 PLHS (mean age 43.5±13.5 years; 57.1% women) not deceased before 1/1/2023 were used for this analysis. Cardiovascular risk factors were frequent in the prevalent population: hypertension (22%), obesity (21%), hypolipidemic treatment (14%), diabetes (11%). Other frequent comorbidities were depression (9%) with a suicide attempt for 4% since 2008. HCRU in 2023 were: consultation with a general practitioner (at least one visit) (85%) and a specialist (70%, including 11% with a dermatologist) in private practices, a physician in a hospital (50%) and a nurse (56%), overnight inpatient stays (14%), day hospitalisations (19%) and emergency consultations (26%). Pharmacological treatments included analgesics (73%), non‑steroidal anti‑inflammatory drugs (37%), corticosteroids (25%), antibiotics (18%), topical fusidic acid (12%), biologics (6.4%). In 2023 the mean cost for the PLHS was 4,680€ and 2,127€ for controls. The main cost drivers were hospital costs (1,730€/730€), drugs (1,084€/331€), devices (316€/91€), consultations (354€/241) and paramedical consultations (257€/99€). Among the 54,832 HS patients aged between 18 and 65 years, 30.3% had a sick leave in 2023 with a mean associated cost for the National Health Insurance of 2,636€ per patient.
CONCLUSIONS: HS imposes a multidimensional burden reflected by comorbidities, extensive HCRU and costs driven by hospitalisations.
METHODS: Data were extracted from the French national claims database (SNDS) for the period 1/1/2008-31/12/2023. PLHS were patients aged ≥13 years identified using an algorithm based on the L73.2 ICD‑10 code, HS‑specific treatments and procedures, alive on 1/1/2023. Controls are subject without HS and matched to the PLHS according to year of birth and gender. The cost is reported from a societal perspective.
RESULTS: 64,189 PLHS (mean age 43.5±13.5 years; 57.1% women) not deceased before 1/1/2023 were used for this analysis. Cardiovascular risk factors were frequent in the prevalent population: hypertension (22%), obesity (21%), hypolipidemic treatment (14%), diabetes (11%). Other frequent comorbidities were depression (9%) with a suicide attempt for 4% since 2008. HCRU in 2023 were: consultation with a general practitioner (at least one visit) (85%) and a specialist (70%, including 11% with a dermatologist) in private practices, a physician in a hospital (50%) and a nurse (56%), overnight inpatient stays (14%), day hospitalisations (19%) and emergency consultations (26%). Pharmacological treatments included analgesics (73%), non‑steroidal anti‑inflammatory drugs (37%), corticosteroids (25%), antibiotics (18%), topical fusidic acid (12%), biologics (6.4%). In 2023 the mean cost for the PLHS was 4,680€ and 2,127€ for controls. The main cost drivers were hospital costs (1,730€/730€), drugs (1,084€/331€), devices (316€/91€), consultations (354€/241) and paramedical consultations (257€/99€). Among the 54,832 HS patients aged between 18 and 65 years, 30.3% had a sick leave in 2023 with a mean associated cost for the National Health Insurance of 2,636€ per patient.
CONCLUSIONS: HS imposes a multidimensional burden reflected by comorbidities, extensive HCRU and costs driven by hospitalisations.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD147
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin), Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)